Gregory B. Brown

Gregory B. Brown, M.D. is a co-founder of HCRx. Currently CEO of Memgen, a biotechnology company, Dr. Brown remains Vice Chairman of HCRx and a member of the Firm’s SAB. Dr. Brown focuses his efforts for HCRx on business development activities and the review of promising therapeutic categories and products. Educated as a transplantation immunologist and trained as a thoracic and vascular surgeon, Dr. Brown practiced thoracic and vascular surgery in a community setting where he also founded and led an HMO. He brings particular expertise in the scientific, technical, clinical, and medical evaluation of products as well as in healthcare systems and payor/reimbursement dynamics. He has been involved in sourcing, diligence, and closing more than $1 billion of royalty investments. Before co-founding HCRx, Dr. Brown was a partner at Paul Capital Partners, where he co-managed that firm’s royalty investments as a member of the royalty management committee. Prior to beginning his principal investment career in 2003, Dr. Brown was co-head of investment banking and head of healthcare at Adams, Harkness & Hill (now Canaccord Genuity) and a ranked biotechnology research analyst at Vector Securities International. Dr. Brown holds a B.A. from Yale, an M.D. from SUNY Upstate Medical Center, and an M.B.A. from Harvard Business School. He currently serves as an outside director on the boards of Aquestive Therapeutics, Caladrius Biosciences, Faron Pharmaceuticals, and FAST Biomedical.